134 related articles for article (PubMed ID: 38507877)
21. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
[TBL] [Abstract][Full Text] [Related]
22. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
24. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
25. Sotorasib: First Approval.
Blair HA
Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated
Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C; Kim DW; Addeo A; Desai J; Schuler M; Tomasini P; Hong DS; Lito P; Tran Q; Jones S; Anderson A; Hindoyan A; Snyder W; Skoulidis F; Li BT
J Clin Oncol; 2023 Jun; 41(18):3311-3317. PubMed ID: 37098232
[No Abstract] [Full Text] [Related]
27. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
28. Sotorasib effective in KRAS-mutant NSCLC.
Sidaway P
Nat Rev Clin Oncol; 2021 Aug; 18(8):470. PubMed ID: 34140669
[No Abstract] [Full Text] [Related]
29. Sotorasib in KRAS
Olivier T; Prasad V
Lancet; 2024 Jan; 403(10422):145. PubMed ID: 38218611
[No Abstract] [Full Text] [Related]
30. Sotorasib in KRAS
Paz-Ares L; Mehta B; Wang Y; Obiozor C; Waterhouse D; de Langen AJ
Lancet; 2024 Jan; 403(10422):145-146. PubMed ID: 38218612
[No Abstract] [Full Text] [Related]
31. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
[TBL] [Abstract][Full Text] [Related]
32. Absorption, Distribution, Metabolism, and Excretion of [
Dahal UP; Rock BM; Rodgers J; Shen X; Wang Z; Wahlstrom JL
Drug Metab Dispos; 2022 May; 50(5):600-612. PubMed ID: 35153196
[TBL] [Abstract][Full Text] [Related]
33. Limited role of
Li HS; Liu CM; Wang Y
Future Oncol; 2022 Jun; 18(19):2433-2443. PubMed ID: 35440164
[TBL] [Abstract][Full Text] [Related]
34. Sotorasib in
Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
[TBL] [Abstract][Full Text] [Related]
35. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Passiglia F; Lucia Reale M; Lo Russo G; Pasello G; Minuti G; Bulotta A; Galetta D; Pelizzari G; Sini C; Bria E; Roca E; Pilotto S; Genova C; Metro G; Citarella F; Chiari R; Cortinovis D; Delmonte A; Russo A; Tiseo M; Cerea G; Carta A; Scotti V; Vavalà T; Brambilla M; Buffoni L; Buosi R; Catania C; Gori S; Grisanti S; Agustoni F; Garbo E; Malapelle U; Novello S
Lung Cancer; 2024 Jan; 187():107444. PubMed ID: 38157806
[TBL] [Abstract][Full Text] [Related]
36. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
37. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
38. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
39. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
40. The KRAS-G12C inhibitor: activity and resistance.
Liu J; Kang R; Tang D
Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
